Stallergenes Greer, Shionogi & Co., Ltd. and CEOLIA Pharma Co. Ltd announced the transition of promotional activities for Actair in Japan. Actair is Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis.
Health Technology Insights: Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair. Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance.
Health Technology Insights: Pediatrix Board Appoints Kurt D. Newman, M.D. as Independent Director
Stallergenes Greer acknowledges Shionogi’s contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies.
Health Technology Insights: IKS Health Announces Strategic Investment In Western Washington Medical Group’s Managed Service Organization
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
